Marine Anti-infective Agents 2020

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (15 August 2020) | Viewed by 3726

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pharmacognosy, University of Vienna, Vienna, Austria
Interests: antibiotics; bioprospecting; secondary metabolites biosynthesis; bacterial genetics; metabolic engineering; synthetic biology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Global health threats from bacterial, fungal, and viral pathogens challenge the current healthcare systems and lead to ever-growing incidents of disability and mortality. Natural products represent a rich source of anti-infective agents, which have been developed into a plethora of human medicines to fight various infections. The marine environment still remains largely unexplored with regard to novel natural products that can be developed into anti-infective drugs. A combined effort of academic researchers and industrial partners toward the bioprospecting of the marine environment, as well as the use of state-of-the-art genomics-based approaches is the key to the discovery of much-needed new anti-infectives.

This Special Issue shall present new research on anti-infective agents of marine origin. Within the scope of this Issue are: (i) the discovery of novel anti-microbial and anti-viral agents from marine organisms; (ii) chemistry- or genetics-based modification of existing marine natural products to improve their potential as anti-infectives; (iii) studies on the mode of action of marine anti-infective agents; (iv) the discovery of new marine anti-infectives and/or the improvement of their production by means of genome mining, metabolic engineering, and synthetic biology.

This Special Issue will bring forth the latest research from various laboratories working in the field of marine natural products. It will comprise a unique collection of articles that could differ in the approaches and scope, while having a common goal: the discovery, development, and characterization of anti-infective agents of marine origin.        

Prof. Dr. Sergey B. Zotchev
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • marine anti-infective agents
  • marine bioprospecting
  • medicinal chemistry
  • mode of action
  • genome mining
  • metabolic engineering
  • synthetic biology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1454 KiB  
Article
Novel Fredericamycin Variant Overproduced by a Streptomycin-Resistant Streptomyces albus subsp. chlorinus Strain
by Marta Rodríguez Estévez, Maksym Myronovskyi, Birgit Rosenkränzer, Thomas Paululat, Lutz Petzke, Jeanette Ristau and Andriy Luzhetskyy
Mar. Drugs 2020, 18(6), 284; https://doi.org/10.3390/md18060284 - 28 May 2020
Cited by 10 | Viewed by 3168
Abstract
Streptomycetes are an important source of natural products potentially applicable in the pharmaceutical industry. Many of these drugs are secondary metabolites whose biosynthetic genes are very often poorly expressed under laboratory cultivation conditions. In many cases, antibiotic-resistant mutants exhibit increased production of natural [...] Read more.
Streptomycetes are an important source of natural products potentially applicable in the pharmaceutical industry. Many of these drugs are secondary metabolites whose biosynthetic genes are very often poorly expressed under laboratory cultivation conditions. In many cases, antibiotic-resistant mutants exhibit increased production of natural drugs, which facilitates the identification and isolation of new substances. In this study, we report the induction of a type II polyketide synthase gene cluster in the marine strain Streptomyces albus subsp. chlorinus through the selection of streptomycin-resistant mutants, resulting in overproduction of the novel compound fredericamycin C2 (1). Fredericamycin C2 (1) is structurally related to the potent antitumor drug lead fredericamycin A. Full article
(This article belongs to the Special Issue Marine Anti-infective Agents 2020)
Show Figures

Figure 1

Back to TopTop